

**Regimen Monograph**

[Regimen Name](#) | [Drug Regimen](#) | [Cycle Frequency](#) | [Premedication and Supportive Measures](#) | [Dose Modifications](#) | [Adverse Effects](#) | [Interactions](#) | [Drug Administration and Special Precautions](#) | [Recommended Clinical Monitoring](#) | [Administrative Information](#) | [References](#) | [Other Notes](#) | [Disclaimer](#)

**A - Regimen Name**

# CRBPPACL Regimen

PACLitaxel-CARBOplatin

**Disease Site** Lung - Non-Small Cell

**Intent** Palliative

**Regimen Category** **Evidence-Informed :**

Regimen is considered appropriate as part of the standard care of patients; meaningfully improves outcomes (survival, quality of life), tolerability or costs compared to alternatives (recommended by the Disease Site Team and national consensus body e.g. pan-Canadian Oncology Drug Review, pCODR). Recommendation is based on an appropriately conducted phase III clinical trial relevant to the Canadian context OR (where phase III trials are not feasible) an appropriately sized phase II trial. Regimens where one or more drugs are not approved by Health Canada for any indication will be identified under Rationale and Use.

**Rationale and Uses** Treatment of locally advanced or metastatic lung cancer

[back to top](#)

**B - Drug Regimen**

<a href="#">PACLitaxel</a>	175-200 mg /m <sup>2</sup>	IV over 3 hours	Day 1
<a href="#">CARBOplatin</a>	AUC 5 to 6*	IV	Day 1

\*Adjust Carboplatin dose to AUC target (using Calvert formula) as outlined in "Other Notes" section.

[back to top](#)

**C - Cycle Frequency****REPEAT EVERY 21 DAYS**

For 4 to 6 cycles in responding patients unless disease progression or unacceptable toxicity occurs

[back to top](#)

**D - Premedication and Supportive Measures**

**Antiemetic Regimen:** Moderate + NK1 antagonist (Carboplatin AUC  $\geq$  5)

Also refer to [CCO Antiemetic Recommendations](#).

**Pre-medications (prophylaxis for infusion reaction):**

Paclitaxel\*:

- Dexamethasone 20 mg PO 12- and 6-hours OR Dexamethasone 20 mg IV 30 minutes pre-infusion<sup>†</sup>
- Diphenhydramine 25-50 mg IV/PO 30-60 minutes pre-infusion
- Ranitidine 50 mg IV OR Famotidine 20 mg IV 30-60 minutes pre-infusion

\*Consider **discontinuing** pre-medications for paclitaxel if there was no IR in the first 2 doses.

<sup>†</sup>Oral and IV dexamethasone are both effective at reducing overall IR rates. Some evidence suggests that oral dexamethasone may be more effective for reducing severe reactions; however, adverse effects and compliance remain a concern.

Carboplatin:

- There is insufficient evidence that routine prophylaxis with pre-medications reduce infusion reaction (IR) rates.
- Corticosteroids and H1-receptor antagonists ± H2-receptor antagonists **may** reduce IR rates for some patients (e.g. gynecological patients with a platinum-free interval (PFI) > 12 months or a history of drug allergy who are receiving carboplatin starting from the 7th cycle) but no optimal pre-medication regimen has been established.

[back to top](#)

## E - Dose Modifications

Doses should be modified according to the protocol by which the patient is being treated.

### Dosage with toxicity

#### Suggested Dose Levels for Paclitaxel:

Dose Level	Paclitaxel (mg/m <sup>2</sup> )	Paclitaxel (mg/m <sup>2</sup> )
0	200	175
-1	175	135
-2	150	110

Worst Toxicity (Counts x 10 <sup>9</sup> /L)	Carboplatin	Paclitaxel
ANC < 1.5 for > 7 days	Hold <sup>1</sup> ; No change upon restart	Hold <sup>1</sup> , then Consider adding G-CSF and continue current dose, if appropriate OR ↓ 1 dose level
ANC < 0.5 for ≥ 7 days or Febrile Neutropenia	Hold <sup>1</sup> ; ↓ 1 AUC upon restart	Hold <sup>1</sup> , then Consider adding G-CSF and continue current dose, if appropriate OR ↓ 1 dose level <sup>2</sup>

Platelets < 25 or Thrombocytopenic bleeding	Hold <sup>1</sup> ; ↓ 1 AUC upon restart	Hold <sup>1</sup> ; ↓ 1 dose level upon restart <sup>2</sup>
Grade 2 neuropathy	No change	Omit or consider ↓ 1 dose level
Grade 3 neuropathy	No change	Omit or ↓ 1 dose level <sup>2</sup>
Other Grade 3 non-hematologic toxicity	Hold <sup>1</sup> ; ↓ 1 AUC upon restart	Hold <sup>1</sup> ; ↓ 1 dose level upon restart
Grade 4 non-hematologic toxicity	Discontinue	Discontinue
Any grade cystoid macular edema	No change	Discontinue

<sup>1</sup>Do not start new cycle until ANC  $\geq 1.5 \times 10^9/L$ , platelets  $\geq 100 \times 10^9/L$ , and non-hematological toxicities have recovered to  $\leq$  grade 2.

<sup>2</sup>In some clinical studies, paclitaxel dose started at 200mg/m<sup>2</sup>; If starting at this dose, reduce by 2 dose levels for grade 4 hematologic toxicity, including febrile neutropenia or thrombocytopenic bleeding, or grade 3 neuropathy.

### Management of Infusion-related Reactions:

Also refer to the CCO guideline for detailed description of [Management of Cancer Medication-Related Infusion Reactions](#).

Grade	Management	Re-challenge	
	Carboplatin / Paclitaxel	Carboplatin <sup>#</sup>	Paclitaxel
1 or 2	<ul style="list-style-type: none"> <li>Stop or slow the infusion rate.</li> <li>Manage the symptoms.</li> </ul>	<ul style="list-style-type: none"> <li>Consider pre-medications* and infusing at a reduced infusion rate prior to re-</li> </ul>	<ul style="list-style-type: none"> <li>Consider re-challenge with pre-medications and at a reduced infusion rate.</li> <li>After 2 subsequent</li> </ul>

	<p><b>Restart:</b></p> <ul style="list-style-type: none"> <li>• After symptom resolution, restart with pre-mediations ± reduced infusion rate.</li> </ul>	<p>challenge.</p> <ul style="list-style-type: none"> <li>• May consider adding oral montelukast ± oral acetylsalicylic acid.</li> </ul>	<p>IRs, consider replacing with a different taxane. Give intensified pre-mediations and reduce the infusion rate.</p> <ul style="list-style-type: none"> <li>• May consider adding oral montelukast ± oral acetylsalicylic acid.</li> </ul>
3 or 4	<ul style="list-style-type: none"> <li>• Stop treatment.</li> <li>• Aggressively manage symptoms.</li> </ul>	<ul style="list-style-type: none"> <li>• Re-challenge is discouraged, especially if vital signs have been affected.</li> <li>• Consider desensitization if therapy is necessary.</li> </ul>	<ul style="list-style-type: none"> <li>• Re-challenge is discouraged, especially if vital signs have been affected.</li> <li>• Consider desensitization if therapy is necessary.</li> <li>• There is insufficient evidence to recommend substitution with another taxane at re-challenge.</li> <li>• High cross-reactivity rates have been reported.</li> </ul>

#There is evidence that re-challenging with **cisplatin** after carboplatin reaction can be a viable option, however, exact cross reactivity between platinum agents is not known, but can be as high as 25%.

\*Up to 50% of patients can experience recurrent reactions during re-challenge **despite** using pre-mediations (e.g. corticosteroid and H1/H2-receptor antagonist).

**Hepatic Impairment**

For paclitaxel, caution and dose reduction are advised in patients with moderate to severe hepatic impairment. Patients receiving paclitaxel with hepatic impairment may be at risk of toxicity, especially severe myelosuppression.

Suggested dose modifications are:

Bilirubin		AST/ALT	PACLitaxel (% usual dose)	CARBOplatin (% usual dose)
≤ 1.25 x ULN	AND	2 to 10 x ULN	75%	No change
1.26 to 2.5 x ULN	AND	< 10 x ULN	40%	
2.6 to 4 x ULN	AND	< 10 x ULN	25%	
> 4 x ULN	AND/OR	≥ 10 x ULN	Consider risk-benefit or Omit	

### **Renal Impairment**

Creatinine Clearance (mL/min)	Paclitaxel	Carboplatin
20 - 50	No change	Use Calvert formula*
< 20		Discontinue

\*Refer to "Other Notes" section.

### **Dosage in the Elderly**

No adjustment required, but elderly patients are more at risk for severe toxicity. Caution should be exercised and dose reduction considered with carboplatin as elderly patients may have reduced renal function, more severe myelosuppression and neuropathy.

[back to top](#)

**F - Adverse Effects**

Refer to [PACLitaxel](#), [CARBOplatin](#) drug monograph(s) for additional details of adverse effects.

Very common (≥ 50%)	Common (25-49%)	Less common (10-24%)	Uncommon (< 10%), but may be severe or life-threatening
<ul style="list-style-type: none"> <li>• Alopecia (rarely permanent)</li> <li>• Peripheral neuropathy (may be severe)</li> <li>• Myelosuppression ± infection, bleeding (may be severe)</li> <li>• Musculoskeletal pain</li> <li>• Nausea, vomiting</li> </ul>	<ul style="list-style-type: none"> <li>• Hypersensitivity</li> <li>• Abnormal electrolytes</li> <li>• Nephrotoxicity (may be severe)</li> <li>• Fatigue</li> </ul>	<ul style="list-style-type: none"> <li>• Edema</li> <li>• Mucositis</li> <li>• Constipation</li> <li>• Diarrhea (may be severe)</li> <li>• ↑ LFTs</li> <li>• Hearing impairment</li> <li>• ECG changes</li> </ul>	<ul style="list-style-type: none"> <li>• Arrhythmia, cardiac failure</li> <li>• Arterial / venous thromboembolism</li> <li>• Rash</li> <li>• Radiation recall reaction</li> <li>• GI obstruction / perforation</li> <li>• Hemolytic uremic syndrome</li> <li>• Pancreatitis</li> <li>• Injection site reaction</li> <li>• Secondary malignancy</li> <li>• Autonomic, cranial neuropathy</li> <li>• Encephalopathy</li> <li>• Cystoid macular edema</li> <li>• Seizure</li> <li>• Pneumonitis</li> <li>• Visual disturbances</li> </ul>

[back to top](#)

**G - Interactions**

Refer to [PACLitaxel](#), [CARBOplatin](#) drug monograph(s) for additional details.

- 
- Monitor INR in patients receiving warfarin; warfarin dosage adjustment may be required.
  - Monitor closely with nephrotoxic and ototoxic drugs (ie. aminoglycosides) due to additive effects.
  - Monitor closely with phenytoin; phenytoin dose adjustment may be required.
  - Avoid if possible, or caution with radiation; may increase the risk of radiation pneumonitis.

[back to top](#)

## H - Drug Administration and Special Precautions

Refer to [PACLitaxel](#), [CARBOplatin](#) drug monograph(s) for additional details.

### **Administration**

#### Paclitaxel:

- In order to minimize patients' exposure to DEHP leaching from PVC bags or sets, use polyolefin or polypropylene infusion bags and polyethylene-lined administration sets (with a 0.22 micron in-line filter).
- Dilute in 500-1000 mL Normal Saline or 5% Dextrose, in a final concentration of 0.3-1.2 mg/mL and infuse over 3 hours.
- Extended infusion of paclitaxel is not recommended as primary prophylaxis to reduce paclitaxel IRs.
- Excessive shaking, agitation, or vibration may induce precipitation and should be avoided.
- Precipitation may rarely occur with infusions longer than 3 hours.

#### Carboplatin:

- Mix in 100mL to 250mL bag (5% Dextrose or Normal Saline); infuse IV over 15 to 60 minutes.
- There is insufficient evidence that routine prophylaxis with extended infusion reduces IR rates.
- Incompatible with sets, needles or syringes containing aluminum – leads to precipitation and loss of potency.
- Protect from light.

Also refer to the CCO guideline for detailed description of [Management of Cancer Medication-Related Infusion Reactions](#).



**Contraindications**

- Patients with a history of severe hypersensitivity to platinum-containing compounds, paclitaxel or other drugs formulated in Cremophor EL (polyethoxylated castor oil)
- Patients with pre-existing, severe renal impairment
- Patients with severe myelosuppression or bleeding tumours

**Warnings/Precautions**

- Patients who have received extensive prior treatment, have poor performance status and those over 65 years of age
- Patients with abnormal renal function or who are receiving concomitant nephrotoxic drugs
- Paclitaxel contains ethanol, and is administered with agents such as antihistamines which cause drowsiness. Patients should be cautioned regarding driving and the use of machinery.
- Avoid live vaccines. Reduced immunogenicity may occur with the use of inactivated vaccines.

**Pregnancy/Lactation**

- Carboplatin and paclitaxel are not recommended for use in pregnancy. Adequate contraception should be used by both sexes during treatment, and for at least **6 months** after the last dose.
- Breastfeeding is not recommended.
- Fertility Effects:
  - Carboplatin: Unknown
  - Paclitaxel: Yes

[back to top](#)

## I - Recommended Clinical Monitoring

Treating physicians may decide to monitor more or less frequently for individual patients but should always consider recommendations from the product monograph.

### Recommended Clinical Monitoring

- CBC; baseline and before each cycle
- Liver function tests; baseline and before each cycle
- Renal function tests (including electrolytes); baseline and before each cycle
- Blood pressure and pulse; during paclitaxel infusion
- Ophthalmology, if visual impairment; as clinically indicated
- Clinical assessment of thromboembolism, bleeding, GI effects, infection, musculoskeletal, ototoxicity, neurotoxicity, hypersensitivity and respiratory effects; at each visit
- Grade toxicity using the current [NCI-CTCAE \(Common Terminology Criteria for Adverse Events\) version](#)

### Suggested Clinical Monitoring

- INR; baseline and as clinically indicated
- Continuous cardiac monitoring; during subsequent infusions in patients who developed serious conduction abnormalities
- Cardiac function tests; baseline and as clinically indicated, especially in patients who are close to the lifetime cumulative dose of anthracyclines / anthracenediones

[back to top](#)

## J - Administrative Information

Approximate Patient Visit	5-6 hours
Pharmacy Workload (average time per visit)	30.383 minutes
Nursing Workload (average time per visit)	59.833 minutes

---

[back to top](#)

## K - References

Belani CP, Lee JS, Socinski MA, Robert F, Waterhouse D, Rowland K, et al. Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. *Ann Oncol* 2005;16:1069-75.

Carboplatin and paclitaxel drug monographs, Cancer Care Ontario.

Kelly K, Crowley J, Bunn P, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A southwest oncology group trial. *J Clin Oncol* 2001; 19(13): 3210-8.

Kosmidis PA Kalofonos C, Syrigas K, Skarlos D, Nicolaidis C, Bafaloukos D, et al. Paclitaxel and gemcitabine vs. carboplatin and gemcitabine. A multicenter, phase III randomized trial in patients with advanced inoperable Non-small cell lung cancer (NSCLC) [abstract]. *Proc Am Soc Clin Oncol* 2005;23:621.

Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. *New Engl J Med* 2002; 346:92-8.

Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. *N Engl J Med* 2018;378:2288-301.

### **PEBC Advice Documents or Guidelines**

- [Systemic Treatment for Patients with Advanced Non-Small Cell Lung Cancer](#)

**August 2021** Modified Rationale and Uses section

[back to top](#)

## L - Other Notes

### **Calvert Formula**

**DOSE (mg) = target AUC X (GFR + 25)**

- AUC = product of serum concentration (mg/mL) and time (min)
- GFR (glomerular filtration rate) expressed as measured Creatinine Clearance or estimated from Serum Creatinine (by Cockcroft and Gault method or Jelliffe method)

(Calvert AH, Newell DR, Gumbrell LA, et al, Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. *J Clin Oncol*, 1989; 7: 1748-1756)

[back to top](#)

## M - Disclaimer

### **Regimen Abstracts**

*A Regimen Abstract is an abbreviated version of a Regimen Monograph and contains only top level information on usage, dosing, schedule, cycle length and special notes (if available). It is intended for healthcare providers and is to be used for informational purposes only. It is not intended to constitute or be a substitute for medical advice, and all uses of the Regimen Abstract are subject to clinical judgment. Such information is provided on an “as-is” basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information’s quality, accuracy, currency, completeness, or reliability, and Cancer Care Ontario disclaims all liability for the use of this information, and for any claims, actions, demands or suits that arise from such use.*

*Information in regimen abstracts is accurate to the extent of the ST-QBP regimen master listings, and has not undergone the full review process of a regimen monograph. Full regimen monographs will be published for each ST-QBP regimen as they are developed.*

### **Regimen Monographs**

*Refer to the [New Drug Funding Program](#) or [Ontario Public Drug Programs](#) websites for the most up-to-date public funding information.*

*The information set out in the drug monographs, regimen monographs, appendices and symptom management information (for health professionals) contained in the Drug Formulary (the “Formulary”) is intended for healthcare providers and is to be used for informational purposes only. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects of a particular drug, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for a given condition. The information in the Formulary is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. All uses of the Formulary are subject to clinical judgment and actual prescribing patterns may not follow the information provided in the Formulary.*

*The format and content of the drug monographs, regimen monographs, appendices and symptom management information contained in the Formulary will change as they are reviewed and revised on a periodic basis. The date of last revision will be visible on each page of the monograph and regimen. Since standards of usage are constantly evolving, it is advised that the Formulary not be used as the sole source of information. It is strongly recommended that original references or product monograph be consulted prior to using a chemotherapy regimen for the first time.*

*Some Formulary documents, such as the medication information sheets, regimen information sheets and symptom management information (for patients), are intended for patients. Patients should always consult with their healthcare provider if they have questions regarding any information set out in the Formulary documents.*

*While care has been taken in the preparation of the information contained in the Formulary, such information is provided on an “as-is” basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information’s quality, accuracy, currency, completeness, or reliability.*

*CCO and the Formulary’s content providers shall have no liability, whether direct, indirect, consequential, contingent, special, or incidental, related to or arising from the information in the Formulary or its use thereof, whether based on breach of contract or tort (including negligence), and even if advised of the possibility thereof. Anyone using the*

---

*information in the Formulary does so at his or her own risk, and by using such information, agrees to indemnify CCO and its content providers from any and all liability, loss, damages, costs and expenses (including legal fees and expenses) arising from such person's use of the information in the Formulary.*

[back to top](#)